

1 **COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize**  
2 **BNT162b2 during the first month of rollout**

3

4 Mazin Barry,<sup>a\*</sup> Mohamad-Hani Temsah,<sup>b\*</sup> Fadi Aljamaan,<sup>c,f,g</sup> Basema Saddik,<sup>h,i</sup> Ayman Al-  
5 Eyadhy,<sup>b</sup> Shuliweeh Alenezi,<sup>o</sup> Nurah Alamro,<sup>c,l</sup> Abdullah N Alhuzaimi,<sup>c,d,e</sup> Ali Alhaboob,<sup>b</sup> Khalid  
6 Alhasan,<sup>b</sup> Fahad Alsohime,<sup>b</sup> Ali Alaraj,<sup>g,j</sup> Rabih Halwani,<sup>h,k</sup> Amr Jamal,<sup>c,l,m</sup> Omar Temsah,<sup>n</sup> Fahad  
7 Alzamil,<sup>b</sup> Ali Somily,<sup>c</sup> Jaffar A. Al-Tawfiq<sup>p,q,r</sup>

8 All authors attest they meet the ICMJE criteria for authorship

9 <sup>a</sup> Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King  
10 Saud University and King Saud University Medical City, Riyadh, Saudi Arabia

11 <sup>b</sup> Pediatric Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia

12 <sup>c</sup> College of Medicine, King Saud University, Riyadh, Saudi Arabia

13 <sup>d</sup> Division of Pediatric Cardiology, Department of Cardiac Sciences, King Saud University Medical  
14 City, College of Medicine, King Saud University, Riyadh, Saudi Arabia

15 <sup>e</sup> Heart Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

16 <sup>f</sup> Critical Care Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia

17 <sup>g</sup> Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia

18 <sup>h</sup> Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates

19 <sup>i</sup> Department of Family and Community Medicine, College of Medicine, University of Sharjah,  
20 Sharjah, United Arab Emirates

21 <sup>j</sup> Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia

22 <sup>k</sup> Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United  
23 Arab Emirates

24 <sup>l</sup> Department of Family and Community Medicine, King Saud University Medical City, Riyadh,  
25 Saudi Arabia

26 <sup>m</sup> Evidence-Based Health Care & Knowledge Translation Research Chair, King Saud University,  
27 Riyadh, Saudi Arabia

28 <sup>n</sup> College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

29 <sup>o</sup> Department of Psychiatry, College of Medicine, King Saud University, Riyadh, Saudi Arabia

30 <sup>p</sup> Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare,  
31 Dhahran, Saudi Arabia

32 <sup>q</sup> Infectious Disease Division, Department of Medicine, Indiana University School of Medicine,  
33 Indianapolis, IN, USA

34 <sup>r</sup> Infectious Disease Division, Department of Medicine, Johns Hopkins University School of  
35 Medicine, Baltimore, MD, USA

36

37 \*These authors contributed equally to this research.

38

39 **Correspondence to:**

40 Dr. Mazin Barry; [mbarry@ksu.edu.sa](mailto:mbarry@ksu.edu.sa)

41 Tel: +966-11467-1039

42 Fax: +966-11467-1010

43 College of Medicine

44 King Saud University

45 PO Box 2925

46 Riyadh, 11461

47 Saudi Arabia

48 **Abstract**

49 **Background:**

50 The Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the  
51 BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17,  
52 2020 and first targeted at healthcare workers (HCWs). This study assesses vaccine uptake  
53 among this group during the first month of its availability.

54 **Methods:**

55 A national cross-sectional, pilot-validated, self-administered survey was conducted among  
56 HCWs in the KSA between December 27, 2020 and January 3, 2021. The survey included  
57 sociodemographic details, previous contact with COVID-19 patients, previous infection with  
58 COVID-19, receiving (or registering with the Ministry of Health website to receive) the COVID-19  
59 vaccine, sources of HCWs' information on vaccines, awareness of emerging variants of concern,  
60 and anxiety level using the 7-item Generalized Anxiety Disorder assessment. A descriptive  
61 bivariate analysis and multivariate logistic binary regression analysis were performed. The  
62 primary evaluated outcome was vaccine uptake.

63 **Results:**

64 Of the 1,058 participants who completed the survey, 704 (66.5%) were female, and 626 (59.2%)  
65 were nurses. Of all the respondents, 352 (33.27%) were enrolled to receive or had already  
66 received the vaccine, while 706 (66.73%) had not registered. In a bivariate analysis, not  
67 enrolling for vaccination was more likely in females than males (78.5% vs. 21.5%,  $P < 0.001$ ),  
68 HCWs between the ages of 20 and 40 years than those  $> 40$  years (70.4% vs. 29.6%,  $P = 0.005$ ),  
69 Saudi HCWs than expatriates (78% vs 22%,  $P < 0.001$ ), and among HCWs who used social media

70 as a source of information than those who did not (69.8% vs. 38.6%,  $P < 0.001$ ). In a  
71 multivariate analysis, independent factors for not enrolling to receive the vaccine included  
72 being female (aOR = 0.287, 95%CI = 0.206–0.401,  $P < 0.001$ ), being less than 40 years of age  
73 (aOR = 1.021, 95%CI = 1.002–1.040,  $P = 0.032$ ), and using social media as a source of  
74 information (aOR = 0.207, 95%CI = 0.132–1.354,  $P = 0.001$ ). Factors associated with uptake were  
75 being a Saudi national (aOR = 1.918, 95%CI = 1.363–2.698,  $P < 0.001$ ), working in an intensive  
76 care unit (aOR = 1.495, 95%CI = 1.083–2.063,  $P = 0.014$ ), and working at a university hospital  
77 (aOR = 1.867, 95%CI = 1.380–2.525,  $P < 0.001$ ).

#### 78 **Conclusions:**

79 A low level of vaccine uptake was observed especially in female HCWs, those younger than 40  
80 years old, and those who used social media as their source of vaccine information. This survey  
81 provides important information for public health authorities in order to scale up vaccination  
82 campaigns targeting these HCWs to increase vaccine enrollment and uptake.

83 **Keywords:** COVID-19, BNT162b2, vaccine uptake, healthcare workers, Kingdom of Saudi Arabia

## 84 **1 Introduction**

85           After the coronavirus disease 2019 (COVID-19) reached pandemic levels, vaccine  
86 development was fast tracked through government funding, corporate spending, and private  
87 donations [1]. Once vaccines were made available in December 2020, a phased approach for  
88 vaccine allocation was recommended, with Phase 1a targeting first respondents and healthcare  
89 workers (HCWs) [2]. Several vaccine manufacturers have published their Phase 3 trials  
90 confirming the safety and efficacy of the vaccine [3-5]. However, such unprecedented scientific  
91 achievement is challenged by the hesitancy of HCWs to accept vaccination [6]. In an earlier  
92 study from the Kingdom of Saudi Arabia (KSA), 70% of the 1521 HCWs surveyed were willing to  
93 receive the COVID-19 vaccine [6]. Another study showed that 63% of the nurses surveyed were  
94 willing to receive the COVID-19 vaccine [7]. In two studies, the acceptance of the COVID-19  
95 vaccine among adults was found to be between 58% and 69% [8, 9]. The KSA granted  
96 Pfizer/BioNTech emergency use authorization for the BNT162b2 vaccine on December 10,  
97 2020, becoming the fourth country to do so after the United Kingdom, Bahrain, and Canada [10,  
98 11]. On that same day, the Ministry of Health (MoH) sent out mass short message service texts  
99 and emails to all HCWs in the country encouraging them to voluntarily enroll for vaccine uptake  
100 through a dedicated smartphone application or the MoH website. COVID-19 vaccine rollout  
101 began on December 17, 2020. This study was conducted to evaluate vaccine enrollment and  
102 uptake within the first month of its rollout among HCWs in the KSA.

103

## 104 **2 Method**

### 105 **2.1 Data collection**

106 This national cross-sectional survey was conducted among HCWs in Saudi Arabia during  
107 the COVID-19 pandemic. Data were collected between December 27, 2020 and January 3, 2021.  
108 At the time of data collection, the national coronavirus vaccination campaign had already  
109 begun in the KSA, with HCWs as one of the prioritized groups. HCWs were surveyed regarding  
110 their intention to receive the COVID-19 vaccine. Participants were invited using a convenience  
111 sampling technique. We used several social media platforms and email lists to recruit  
112 participants. The survey was a pilot-validated, self-administered questionnaire that was sent to  
113 HCWs through SurveyMonkey<sup>®</sup>, a platform that allows researchers to deploy and analyze  
114 surveys via the web. The questionnaire was adapted from our previously published studies with  
115 modification and additions related to the new severe acute respiratory syndrome coronavirus 2  
116 (SARS-CoV-2) variant of concern (VoC) [6, 12, 13].

117 The questions asked about respondents' demographic characteristics (job category, age,  
118 gender, years of clinical experience, and work area), previous exposure to COVID-19 patients,  
119 previous COVID-19 infection, and travel history in the prior 3 months. We assessed the level of  
120 intention to and actual receipt (i.e., uptake) of the COVID-19 vaccine among HCWs. In addition,  
121 we assessed factors affecting respondents' intention to receive the COVID-19 vaccine, including  
122 their level of awareness of the new SARS-CoV-2 VoC and sources of information. HCWs' anxiety  
123 was measured by the validated 7-item General Anxiety Disorder (GAD-7) questionnaire, which  
124 has been used in several studies assessing HCWs' anxiety levels during the pandemic [13, 14].

125 HCWs were informed of the purpose of the study in English at the beginning of the  
126 online survey. The respondents were given the opportunity to ask questions via a dedicated  
127 email address for the study. The Institutional Review Board at the College of Medicine and King  
128 Saud University Medical City approved the study (approval #20/0065/IRB). A waiver for signed  
129 consent was obtained since the survey presented no more than a minimal risk to subjects and  
130 involved no procedures for which written consent is usually required. To maximize  
131 confidentiality, personal identifiers were not required.

132

## 133 **2.2 Statistical analyses**

134 Descriptive analyses with means and standard deviations were applied to continuous  
135 variables, and categorically measured variables were described with frequencies and  
136 percentages. Histograms and statistical Kolmogorov–Smirnov tests of normality were used to  
137 assess the statistical normality of continuous variables. HCWs’ awareness of the new mutagenic  
138 COVID-19 virus strain was measured with eight questions, which received a score of 1 for each  
139 correctly answered knowledge/awareness question and 0 for each incorrectly answered  
140 question. Total awareness of the mutagenic viral outbreak was measured by adding up the total  
141 scores on the knowledge indicators, yielding a mutagenic disease awareness ranging from 0 to  
142 8 points.

143 Independent samples t-tests were used to assess the statistical significance of mean  
144 scores between the levels of dichotomous categorical variables. Chi-squared tests of  
145 independence were used to assess the associations between categorically measured variables  
146 with the HCWs’ uptake of the COVID-19 vaccine. The logistic binary regression analysis was

147 used to understand HCWs' immunization uptake by regressing their sociodemographic, clinical,  
 148 and professional characteristics and mutant viral strain perceptions against their odds of having  
 149 actively received the COVID-19 immunization shot or registering for it. The associations  
 150 between HCWs' measured independent variables and COVID-19 vaccine uptake were expressed  
 151 as adjusted odds ratios (aOR) with 95% confidence intervals (95%CI). IBM® SPSS® was used for  
 152 the statistical data analysis, and significance was considered at the 0.05 alpha level.

153

### 154 3 Results

155 Of the 1,212 HCWs who accessed the survey, 1,058 (87.2%) completed the survey. Their  
 156 sociodemographic characteristics are shown in Table 1.

157

158 **Table 1:** Descriptive analysis of HCWs' sociodemographic and professional characteristics (N =  
 159 1058)

Characteristic	n	%
<b>Gender</b>		
Male	354	33.5
Female	704	66.5
<b>Age</b>		
20–30 years	238	22.5
31–40 years	471	44.5
41–50 years	263	24.9
≥ 51 years	86	8.1
<b>Marital state</b>		
Single	257	24.3
Married/divorced/widowed	801	75.7
<b>Nationality</b>		
Expatriate	736	69.6
Saudi	322	30.4
<b>Clinical Role</b>		
Consultant	213	20.1
Assistant consultant/fellow	52	4.9



Resident/registrar	138	13.0
Nurse	626	59.2
Intern/medical student	29	2.7
<b>Hospital Area</b>		
ICU	273	25.8
ER	110	10.4
OR	62	5.9
Isolation ward	63	6.0
General ward	261	24.7
OPD	225	21.3
Non-clinical area	64	6.0
<b>Hospital sector</b>		
Private	174	16.4
Public/governmental	487	46.0
University hospital	397	37.5
<b>Hospital specialty</b>		
Primary healthcare center	123	11.6
Secondary care hospital	196	18.5
Tertiary hospital	739	69.8

160 ICU: intensive care unit; ER: emergency room; OR: operating room; OPD: outpatient department.

161

162 Of all the respondents, 352 (33.27%) were enrolled to receive or had already received  
163 the vaccine, while 706 (66.73%) did not wish to register for vaccination. The bivariate analysis  
164 of association between the respondents' characteristics and their tendency to receive the  
165 vaccine is shown in Table 2. A significantly higher percentage of females compared to males  
166 reported not receiving or registering to receive the vaccine (78.5% vs. 21.5%,  $P < 0.001$ ), and  
167 younger age (between 20 and 40 years old) was associated with a significant tendency to  
168 decline to receive the vaccine compared to older age groups ( $P = 0.005$ ). A lower percentage of  
169 expatriates reported receiving or registering to receive the vaccine compared to Saudi nationals  
170 ( $P < 0.001$ ).

171 A significantly higher percentage of nurses (69.5%) and HCWs working in  
172 public/governmental hospitals (49.8%) had not received or registered to receive the vaccine in

173 comparison to other clinical roles (P < 0.001) and HCWs in other hospital sectors (P = 0.002).  
 174 HCWs working in university hospitals (44.9%, P = 0.002) and tertiary care hospitals (74.1%, P =  
 175 0.048) were more inclined to receive the vaccine.

176 HCWs' previous infection with laboratory-confirmed COVID-19, previous contact with  
 177 COVID-19 patients, and their travel history over the last 3 months were not correlated with  
 178 their vaccine uptake. The respondents who were inclined to receive the vaccine were  
 179 significantly less dependent on using social media as a source of information and had a  
 180 significantly lower GAD-7 score, higher awareness about the new VoC, and lower level of worry  
 181 about travelling abroad.

182

183 **Table 2:** Descriptive bivariate analysis of HCWs' uptake of the COVID-19 vaccine (N = 1058)

Characteristic	Immunization uptake		Test statistic	P value
	Not yet received	n (%) Received/ registered		
<b>Gender</b>				
Male	152 (21.5)	202 (57.4)	$\chi^2(1) = 135.6$	< 0.001
Female	554 (78.5)	150 (42.6)		
<b>Age</b>				
20–30 years	171 (24.2)	67 (19.0)	$\chi^2(1) = 12.90$	0.005
31–40 years	326 (46.2)	145 (41.2)		
41–50 years	162 (22.9)	101 (28.7)		
≥ 51 years	47 (6.7)	39 (11.1)		
<b>Marital state</b>				
Single	177 (25.1)	80 (22.7)	$\chi^2(1) = 0.70$	0.402
Married/divorced/widowed	429 (74.9)	272 (77.3)		

<b>Nationality</b>					
Expatriate	551 (78.0)	185 (52.6)	$\chi^2(1) = 72.1$	< 0.001	
Saudi	155 (22.0)	167 (47.4)			
<b>Clinical Role</b>					
Consultant	93 (13.2)	120 (34.1)	$\chi^2(4) = 102.4$	< 0.001	
Assistant consultant/fellow	31 (4.4)	21 (6.0)			
Resident/registrar	74 (10.5)	64 (18.2)			
Nurse	491 (69.5)	135 (38.4)			
Intern/medical student	17 (2.4)	12 (3.4)			
<b>Hospital ward</b>					
ICU	163 (23.1)	110 (31.2)	$\chi^2(6) = 10.60$	0.102	
ER	83 (11.8)	27 (7.7)			
OR	41 (5.8)	21 (6.0)			
Isolation ward	43 (6.1)	20 (5.7)			
General ward	179 (25.4)	82 (23.3)			
OPD	153 (24.7)	72 (20.5)			
Non-clinical area	44 (6.2)	20 (5.7)			
<b>Hospital sector</b>					
Private	122 (17.3)	52 (14.8)	$\chi^2(2) = 12.23$	0.002	
Public/governmental	345 (48.9)	42 (40.3)			
University hospital	239 (33.9)	158 (44.9)			
<b>Hospital specialty</b>					
Primary healthcare center	83 (11.8)	40 (11.4)	$\chi^2(2) = 6.10$	0.048	
Secondary care hospital	145 (20.5)	51 (14.5)			
Tertiary hospital	478 (67.7)	261 (74.1)			
<b>Had contact with patients infected with COVID-19</b>					
No	156 (22.1)	77 (21.9)	$\chi^2(1) = 0.010$	0.935	
Yes	550 (77.9)	275 (78.1)			
<b>Previously diagnosed with PCR-positive COVID-19</b>					
No	640 (90.7)	322 (91.5)	$\chi^2(1) = 0.194$	0.660	

Yes	66 (9.3)	30 (8.5)		
<b>Traveled abroad in the last 3 months</b>				
No	669 (94.8)	329 (93.5)	$\chi^2(1) = 0.73$	0.391
Yes	37 (5.2)	23 (6.5)		
<b>Use of social media as a source of information</b>				
No	213 (30.2)	136 (38.6)	$\chi^2(1) = 7.62$	< 0.001
Yes	493 (69.8)	216 (61.4)		
<b>GAD-7 score</b>	5.29 (5.10)	4.36 (4.75)	t(1056) = 2.85	0.004
<b>Awareness of the COVID-19 VoC mean score</b>	3.59 (1.13)	4.10 (1.40)	t(601.8) = 6.03	< 0.001
<b>Perceived worry level about travelling abroad</b>	3.30 (1.17)	3.10 (1.90)	t(1058) = 3.10	0.002

184 PCR: polymerase chain reaction, ICU: intensive care unit; ER: emergency room; OR: operating room; OPD:  
 185 outpatient department, GAD-7: General Anxiety Disorder score, VoC: variant of concern  
 186

187


188 A binomial logistic regression was performed to analyze the independent association between  
 189 HCWs' characteristics and their vaccine uptake behavior as shown in Table 3. Females were  
 190 significantly less likely to receive or register to receive the vaccine (aOR = 0.287, P < 0.001),  
 191 while older age (aOR = 1.021, P = 0.032) and Saudi nationality (aOR = 1.918, P = 0.001) were  
 192 associated with an increased likelihood of vaccine uptake. Intensive care unit (ICU) staff (aOR =  
 193 1.495, P = 0.014) and staff working in university hospitals (aOR = 1.867, P < 0.001) were also  
 194 significantly and independently more likely to receive or register to receive the vaccine. A  
 195 higher level of awareness of the VoC also significantly predicted vaccine uptake among HCWs  
 196 (aOR = 1.131, P = 0.047). HCWs' level of anxiety as measured by their GAD-7 score, history of  
 197 travelling abroad over the previous 3 months, and personal history of previous polymerase  
 198 chain reaction (PCR)-positive COVID-19 did not independently predict their vaccine uptake

199 behavior. Figure 1 illustrates the linear incremental relation between HCWs' age and the  
 200 probability of vaccine uptake, as the probability rose from about 30% for the 20–31 age group  
 201 to almost 45% for those over 50 years of age.

202 **Table 3:** Multivariate logistic binary regression analysis of HCWs' COVID-19 immunization  
 203 behavior (registering or receiving the vaccine) (N = 1058)

Characteristic	Multivariate aOR	95%CI		P value
		Lower	Upper	
Gender = Female	0.287	0.206	0.401	< 0.001
Age above 40 years	1.021	1.002	1.040	0.032
Marital status = Married/divorced/widowed	0.799	0.545	1.169	0.247
Nationality = Saudi	1.918	1.363	2.698	< 0.001
Hospital ward = ICU	1.495	1.083	2.063	0.014
Hospital sector = University hospital	1.867	1.380	2.525	< 0.001
Mean score awareness of variant of concern (range: 0–8 points)	1.131	1.002	1.278	0.047
GAD-7 score	0.995	0.966	1.025	0.742
Travelled abroad in last 3 months	1.624	0.889	2.964	0.114
Previously diagnosed with COVID-19	0.880	0.536	1.445	0.614
Use of social media as a source of information	0.207	0.132	1.354	0.001

204 ICU: intensive care unit, GAD-7: General Anxiety Disorder score



206

207 **Figure 1:** The association between HCWs' age group and their model mean predicted  
208 probability of COVID-19 vaccination.

209

#### 210 **4 Discussion**

211 In this reported national survey on COVID-19 vaccine uptake in one of the first countries  
212 to roll out the BNT162b2 vaccine, only 352 (33.3%) of 1,058 HCWs had either registered  
213 to/received the vaccine within 3 weeks of its availability. In a previous cross-sectional survey to  
214 assess HCWs' COVID-19 vaccine confidence and hesitancy prior to launching a vaccine campaign  
215 in the KSA, 70% were willing to receive a vaccine once available[6]. Additionally, half of the  
216 participants indicated that they would receive the vaccine as soon as it became available, while  
217 more than one-third preferred delaying receiving it for a few months. In a study that specifically

218 focused on vaccine acceptance according to vaccine type, only 20.9% were willing to receive  
219 BNT162b2 [15]. The low vaccine uptake reported in the current study, together with HCWs'  
220 earlier reports of preferring to delay getting vaccinated, is alarming and should trigger public  
221 health officials to target these groups with campaigns to enhance their vaccine confidence and  
222 acceptance.

223           In the current study, two-thirds of participants were female, almost 60% were nurses,  
224 70% were expatriates, and the majority worked at tertiary care hospitals. These findings are  
225 similar to a previous study that was conducted prior to the vaccine rollout [6]. However, that  
226 study included only 50% nurses. In this study, 69% of nurses had neither received nor registered  
227 to receive the vaccine, while half of the physicians had. This is similar to influenza vaccine  
228 uptake among HCWs, as it has been reported that physicians have significantly higher flu  
229 vaccination rates compared to nurses [16, 17].

230           Almost all of the participants worked in clinical areas, and 80% managed COVID-19  
231 patients. HCWs working in clinical areas other than the ICU, such as the emergency room (ER)  
232 and wards, did not converge significantly on their vaccine uptake. In an influenza vaccine  
233 uptake study, only working in the building where the vaccination was being performed made a  
234 significant difference [18].

235           HCWs from university hospitals were found to be significantly more likely to receive the  
236 vaccine than those working in private and public sectors. Additionally, HCWs in tertiary  
237 healthcare settings were significantly more likely to get the vaccine than those working in  
238 primary and secondary healthcare settings. In a systematic review on influenza vaccination  
239 among HCWs, the top reason for vaccine uptake was self-protection rather than protecting

240 patients or setting an example for their patients, with no observed difference in hospital  
241 settings [19].

242 A gender difference was observed in the vaccine uptake, with female HCWs being  
243 significantly less likely to receive the vaccine than male HCWs ( $P < 0.001$ ). The discrepancy  
244 between males and females in the uptake of this vaccine is interesting. Male sex was shown to  
245 be associated with increased death and ICU admission in a recent meta-analysis of COVID-19  
246 patients [20]. However, anti-Spike antibodies declined faster in female than male patients in a  
247 recent French study [21]. These differences are important to further enhance our  
248 understanding of vaccine uptake and design-specific interventions.

249 While another study showed no effect of age on COVID-19 vaccine acceptance among  
250 the general population [22], our study revealed that HCWs over 40 years of age were more  
251 motivated to receive the vaccine. This is in contrast to a vaccine intent survey among nurses  
252 that showed a stronger COVID-19 vaccination intention among younger workers [7]. While  
253 older HCWs are at a higher risk of COVID-19 infection, protection of the entire healthcare  
254 workforce is crucial during this pandemic.

255 Saudi HCWs were found to be significantly more likely to receive the vaccine than  
256 expatriates ( $P < 0.001$ ). The KSA has made the COVID-19 vaccine available free of charge to all  
257 citizens and residents. A previous study found a disparity in the outcome of patients infected  
258 with SARS-CoV-2 in relation to gender and ethnicity [23]. In a study among blood donors in the  
259 KSA, non-Saudis were found to be more likely to have positive SARS-CoV-2 serology [24]. These  
260 differences between Saudi and expatriates deserve further study in order to understand the  
261 factors contributing to this disparity, which could allow for strategies and communication plans



262 to alleviate the risk of exposure to SARS-CoV-2 and enhance the acceptance of the COVID-19  
263 vaccine among the population.

264 HCWs' clinical role was correlated with their uptake of the vaccine in the bivariate  
265 analysis. Nurses were found to be significantly less inclined to receive the vaccine than  
266 physicians and other professionals ( $P < 0.001$ ), which is similar to a previous study from the KSA  
267 [6]. The multivariate analysis did not show any significant differences between location with the  
268 exception of ICU staff, who were significantly more inclined to receive the vaccine (aOR = 1.495,  
269  $P = 0.014$ ). HCWs are more likely to acquire vaccine-preventable diseases, with 20% of HCWs  
270 contracting influenza annually, recent reports showed low influenza vaccine uptake among  
271 doctors and nurses (56.5% and 34.8% acceptance rate, respectively)[25].

272 Interestingly, no significant differences in vaccine uptake were found between HCWs  
273 who managed COVID-19 patients compared to those who did not or between HCWs with  
274 previous COVID-19 infections compared to those without. The low COVID-19 vaccine uptake  
275 rate in the middle of a pandemic is alarming, and efforts should focus on increasing vaccine  
276 acceptance and uptake to match the speed of the pandemic.

277 The VoC-202012/01 emerged in December 2020, resulting in new travel restrictions  
278 [26]. However, there is evidence that the BNT162b2 vaccine is effective against this variant  
279 based on in-vitro studies [27]. In this study, vaccine uptake was not influenced by HCWs' travel  
280 history. However, the overall sample size of returning travelers was small and may not be  
281 representative. Information on evolving variants are emerging in various countries [28], and  
282 concerns regarding the vaccine's efficacy against these variants may hinder vaccine uptake. This  
283 is a concerning situation that warrants further study.

284 Even before the COVID-19 pandemic, vaccination was considered an emotionally  
285 charged topic in many cultures [29]. However, vaccine hesitancy is common and includes  
286 people who have not yet rejected vaccination but do not trust the institutions connected to the  
287 vaccine [30]. Current recommendations suggest not only to make a safe and effective vaccine  
288 available but also deep engagement of around the human element to build public trust in any  
289 vaccine [31]. This highlights the importance of addressing societal concerns and fears to ensure  
290 a vaccination campaign's success [32]. Personal worries and baseline anxiety should not be  
291 neglected as these could trigger vaccine refusal in the community via the butterfly effect.  
292 Findings in the current study highlight how HCWs, especially those with lower GAD-7 scores,  
293 were more likely to accept the new vaccine. It also provides a glimpse of the relationship  
294 between higher awareness (in this case, of the new variant) and the likelihood of considering  
295 vaccination.

296 The use of social media for information could greatly affect HCWs' and the general  
297 populations' COVID-19 vaccine acceptance. While some studies did not find associations  
298 between willingness to vaccinate and social media use [22, 33], others found a higher  
299 vaccination willingness among respondents from the general population who did not rely on  
300 social media for COVID-19 information [34, 35]. One study assessed the attitudes towards  
301 COVID-19 vaccines using the Vaccine Conspiracy Belief Scale and showed higher conspiracy  
302 beliefs among respondents who relied on social media platforms as their main source of  
303 information [35].

304

305 **4.1 Study limitations and strengths/future potential**

306 This study is subject to the limitations of cross-sectional surveys, including sampling,  
307 response, and recall biases. While this work did not explore the reasons why HCWs did not  
308 register for the vaccine, it presents their initial vaccination acceptance, which needs to be  
309 explored in future studies. It should be noted that HCWs' perceptions and vaccine hesitancy  
310 may differ from one country to another.

311

312 **4.2 Conclusion**

313 This study observed a low level of COVID-19 vaccine enrollment among HCWs during the  
314 first month of the vaccine rollout in one of the first countries to roll out the vaccine. Public  
315 health officials should scale up their efforts to increase vaccine acceptance and uptake among  
316 HCWs to match the speed of the growing pandemic. Optimizing protection of HCWs through  
317 vaccination and encouraging them to subsequently recommend vaccination to their patients is  
318 vital to curbing this global crisis.

319

320 **Conflict of interest:** None declared.

321 **Funding:** This research did not receive any specific grant from funding agencies in the public,  
322 commercial, or not-for-profit sectors.

323

324 **Ethics approval and consent to participate:** The study was approved by the institutional review  
325 board of King Saud University (approval #20/0065/IRB).

326



328 **References**

- 329 [1] Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. *N Engl J*  
330 *Med* 2020;382:1969-73.
- 331 [2] National Academies of Sciences, Engineering, and Medicine. Framework for equitable allocation of  
332 COVID-19 vaccine. 2020.
- 333 [3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the  
334 BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383:2603-15.
- 335 [4] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-  
336 1273 SARS-CoV-2 vaccine. *N Engl J Med* 2020.
- 337 [5] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of  
338 the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four  
339 randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2020;397:99-111.
- 340 [6] Barry M, Temsah M-H, Alhuzaimi A, Alamro N, Al-Eyadhy A, Aljamaan F, et al. COVID-19 vaccine  
341 confidence and hesitancy among healthcare workers: a cross-sectional survey from a MERS-CoV  
342 experienced nation. *medRxiv*. 2020.
- 343 [7] Kwok KO, Li K-K, Wei WI, Tang A, Wong SYS, Lee SS. Influenza vaccine uptake, COVID-19  
344 vaccination intention and vaccine hesitancy among nurses: a survey. *Int J Nurs Stud*  
345 2020;114:103854.
- 346 [8] Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United  
347 States: how many people would get vaccinated? *Vaccine* 2020;38:6500-7.
- 348 [9] Head KJ, Kasting ML, Sturm LA, Hartsock JA, Zimet GD. A national survey assessing SARS-CoV-2  
349 vaccination intentions: implications for future public health communication efforts. *Sci Commun*  
350 2020;42:698-723.

- 351 [10] SFDA. Approved registration of Pfizer-BioNTech COVID-19 vaccine in the Kingdom of Saudi  
352 Arabia. 2020.
- 353 [11] Craven J. COVID-19 vaccine tracker. Regulatory Affairs Professionals Society. 2020.
- 354 [12] Temsah MH, Alhuzaimi AN, Alamro N, Alrabiaah A, Al-Sohime F, Alhasan K, et al. Knowledge,  
355 attitudes, and practices of healthcare workers during the early COVID-19 pandemic in a main,  
356 academic tertiary care centre in Saudi Arabia. *Epidemiol Infect* 2020;1-29.
- 357 [13] Temsah MH, Al-Sohime F, Alamro N, Al-Eyadhy A, Al-Hasan K, Jamal A, et al. The psychological  
358 impact of COVID-19 pandemic on health care workers in a MERS-CoV endemic country. *J Infect*  
359 *Public Health* 2020;13:877-82.
- 360 [14] Xiaoming X, Ming A, Su H, Wo W, Jianmei C, Qi Z, et al. The psychological status of 8817 hospital  
361 workers during COVID-19 epidemic: a cross-sectional study in Chongqing. *J Affect Disord*  
362 2020;276:555-61.
- 363 [15] Temsah MH, Barry M, Aljamaan F, Alhuzaimi A, Al-Eyadhy A, Saddik B, et al. Adenovirus and RNA-  
364 based COVID-19 vaccines: perceptions and acceptance among healthcare workers. medRxiv. 2020.
- 365 [16] Martinello RA, Jones L, Topal JE. Correlation between healthcare workers' knowledge of influenza  
366 vaccine and vaccine receipt. *Infect Control Hosp Epidemiol* 2003;24:845-7.
- 367 [17] Schult TM, Awosika ER, Hodgson MJ, Hirsch PR, Nichol KL, Dyrenforth SR, et al. Innovative  
368 approaches for understanding seasonal influenza vaccine declination in healthcare personnel  
369 support development of new campaign strategies. *Infect Control Hosp Epidemiol* 2012;33:924-31.
- 370 [18] Bautista D, Vila B, Uso R, Tellez M, Zanon V. Predisposing, reinforcing, and enabling factors  
371 influencing influenza vaccination acceptance among healthcare workers. *Infect Control Hosp*  
372 *Epidemiol* 2006;27:73-7.
- 373 [19] Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in  
374 hospitals: a review of studies on attitudes and predictors. *Vaccine* 2009;27:3935-44.

- 375 [20] Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex  
376 identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nat*  
377 *Commun* 2020;11:1-10.
- 378 [21] Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. Sex differences in the  
379 decline of neutralizing antibodies to SARS-CoV-2. *medRxiv*. 2020.
- 380 [22] Alley SJ, Stanton R, Browne M, To QG, Khalesi S, Williams SL, et al. As the pandemic progresses,  
381 how does willingness to vaccinate against COVID-19 evolve? *Int J Environ Res Public Health*  
382 2021;18.
- 383 [23] Tirupathi R, Muradova V, Shekhar R, Salim SA, Al-Tawfiq JA, Palabindala V. COVID-19 disparity  
384 among racial and ethnic minorities in the US: a cross sectional analysis. *Travel Med Infect Dis*  
385 2020;38:101904.
- 386 [24] Banjar A, Al-Tawfiq JA, Alruwaily A, Alserehi H, Al-Qunaibet A, Alaswad R, et al. Seroprevalence of  
387 antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi  
388 Arabia. *Int J Infect Dis*. 2021.
- 389 [25] von Linstow ML, Nordmann Winther T, Eltvedt A, Bybeck Nielsen A, Yde Nielsen A, Poulsen A. Self-  
390 reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare  
391 workers in Denmark. *Vaccine* 2020;38:6570-7.
- 392 [26] ECDC. Risk related to spread of new SARSCoV-2 variants of concern in the EU/EEA.
- 393 [27] Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, et al. Neutralization of N501Y mutant  
394 SARS-CoV-2 by BNT162b2 vaccine-elicited sera. *bioRxiv*.2021.01. 07.425740.
- 395 [28] CDC. New COVID-19 variants.
- 396 [29] Ozawa S, Stack ML. Public trust and vaccine acceptance: international perspectives. *Hum Vaccines*  
397 *Immunother* 2013;9:1774-8.

- 398 [30] Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: a critical review. *Soc Sci*  
399 *Med* 2014;112:1-11.
- 400 [31] Schoch-Spana M, Brunson EK, Long R, Ruth A, Ravi SJ, Trotochaud M, et al. The public's role in  
401 COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine  
402 awareness, access, and acceptance in the United States. *Vaccine*. 2020.
- 403 [32] Ropeik D. How society should respond to the risk of vaccine rejection. *Hum Vaccin Immunother*  
404 2013;9:1815-8.
- 405 [33] Temsah M-H, Alhuzaimi AN, Alrabiaah A, Alamro N, Alsohime F, Al-Eyadhy A, et al. Changes in  
406 healthcare workers' knowledge, attitudes, practices, and stress during the COVID-19 pandemic.  
407 *medRxiv*. 2021:2021.01.19.21250126.
- 408 [34] Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: results of a nationwide  
409 survey. *Vaccine*. 2021.
- 410 [35] Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High rates of COVID-19  
411 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among  
412 other Arab countries. *Vaccines (Basel)* 2021;9.
- 413